BackSolid Biosciences Overview
Solid Biosciences Inc

Solid Biosciences Debt to Equity

Latest debt-to-equity ratio for Solid Biosciences: 0.05 — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

Debt to Equity

0.05

Debt to Equity

0.05

Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.

Debt to Equity (Comparison Companies)

Loading

Debt to Equity History

Loading

Debt to Equity Comparison

Loading

Solid Biosciences (SLDB) FAQ

As of the most recent data, SLDB shows a debt-to-equity ratio of 0.05. That is below the Healthcare sector average of 0.26. Scroll down for historical charts and peer comparison views.

The Healthcare sector average debt-to-equity ratio is about 0.26. Solid Biosciences is at 0.05, which is lower that average. That is roughly 79.6% below the sector mean. Use the comparison chart on this page to see how SLDB stacks up against individual peers as well.

Investors watch SLDB's debt-to-equity ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Solid Biosciences's latest reading is 0.05. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.

Besides this debt-to-equity ratio page, Stockcircle has Solid Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect debt-to-equity ratio (currently 0.05) with ownership activity and broader fundamentals.

The Healthcare average debt-to-equity ratio is about 0.26, while SLDB is at 0.05. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.